Details for New Drug Application (NDA): 213978
✉ Email this page to a colleague
The generic ingredient in TYRVAYA is varenicline tartrate. There are twelve drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the varenicline tartrate profile page.
Summary for 213978
Tradename: | TYRVAYA |
Applicant: | Oyster Point Pharma |
Ingredient: | varenicline tartrate |
Patents: | 10 |
Pharmacology for NDA: 213978
Mechanism of Action | Cholinergic Agonists Partial Cholinergic Nicotinic Agonists |
Medical Subject Heading (MeSH) Categories for 213978
Suppliers and Packaging for NDA: 213978
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
TYRVAYA | varenicline tartrate | SPRAY;NASAL | 213978 | NDA | Oyster Point Pharma | 73521-030 | 73521-030-02 | 2 BOTTLE, PUMP in 1 CARTON (73521-030-02) / 4.2 mL in 1 BOTTLE, PUMP |
TYRVAYA | varenicline tartrate | SPRAY;NASAL | 213978 | NDA | Oyster Point Pharma | 73521-030 | 73521-030-90 | 1 BOTTLE, PUMP in 1 CARTON (73521-030-90) / 4.2 mL in 1 BOTTLE, PUMP |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SPRAY;NASAL | Strength | EQ 0.03MG BASE/SPRAY | ||||
Approval Date: | Oct 15, 2021 | TE: | RLD: | Yes | |||||
Regulatory Exclusivity Expiration: | Oct 15, 2024 | ||||||||
Regulatory Exclusivity Use: | NEW PRODUCT | ||||||||
Patent: | 10,456,396 | Patent Expiration: | Oct 19, 2035 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patented Use: | TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED) | ||||||||
Patent: | 11,224,598 | Patent Expiration: | Oct 19, 2035 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED) |
Complete Access Available with Subscription